Literature DB >> 12186269

Glycine modulators in schizophrenia.

Daniel C Javitt1.   

Abstract

N-methyl-D-aspartate (NMDA) receptor dysfunction may play a key role in the pathophysiology of schizophrenia. Recent studies have investigated the ability of NMDA/glycine-site modulators to ameliorate persistent negative and cognitive symptoms. Several full or partial glycine-site agonists, including glycine, D-serine and D-cycloserine, have shown effectiveness in small-scale clinical trials. Glycine levels in brain are regulated by GLYT1-type glycine transporters. Recently developed glycine transport inhibitors (GTI) have preclinical behavioral effects similar to those of glycine or D-serine, and may represent a 'next generation' approach to the treatment of the persistent negative and cognitive symptoms of schizophrenia.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12186269

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  13 in total

1.  SLC36A4 (hPAT4) is a high affinity amino acid transporter when expressed in Xenopus laevis oocytes.

Authors:  Samyuktha Muralidharan Pillai; David Meredith
Journal:  J Biol Chem       Date:  2010-11-19       Impact factor: 5.157

Review 2.  N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.

Authors:  Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2005-03-10       Impact factor: 4.530

3.  Reduced cortical thickness is associated with the glutamatergic regulatory gene risk variant DAOA Arg30Lys in schizophrenia.

Authors:  C Christoph Schultz; Igor Nenadic; Kathrin Koch; Gerd Wagner; Martin Roebel; Claudia Schachtzabel; Thomas W Mühleisen; Markus M Nöthen; Sven Cichon; Thomas Deufel; Michael Kiehntopf; Marcella Rietschel; Jürgen R Reichenbach; Heinrich Sauer; Ralf G M Schlösser
Journal:  Neuropsychopharmacology       Date:  2011-04-20       Impact factor: 7.853

4.  Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia.

Authors:  Tatiana Lipina; Viviane Labrie; Ina Weiner; John Roder
Journal:  Psychopharmacology (Berl)       Date:  2005-03-10       Impact factor: 4.530

Review 5.  Influence of the NR3A subunit on NMDA receptor functions.

Authors:  Maile A Henson; Adam C Roberts; Isabel Pérez-Otaño; Benjamin D Philpot
Journal:  Prog Neurobiol       Date:  2010-01-25       Impact factor: 11.685

Review 6.  Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia.

Authors:  Bita Moghaddam
Journal:  Psychopharmacology (Berl)       Date:  2004-02-19       Impact factor: 4.530

Review 7.  [Mismatch negativity in schizophrenia research. An indicator of early processing disorders of acoustic information].

Authors:  T Rosburg; I Kreitschmann-Andermahr; H Sauer
Journal:  Nervenarzt       Date:  2004-07       Impact factor: 1.214

8.  Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex.

Authors:  Lucas Lecourtier; Houman Homayoun; Gilles Tamagnan; Bita Moghaddam
Journal:  Biol Psychiatry       Date:  2007-05-23       Impact factor: 13.382

Review 9.  The N-methyl D-aspartate receptor glycine site and D-serine metabolism: an evolutionary perspective.

Authors:  Michael J Schell
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2004-06-29       Impact factor: 6.237

10.  Early stage development of the glycine-1 re-uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men.

Authors:  Marieke Liem-Moolenaar; Pierre Peeters; Ingrid M C Kamerling; Chris Hogg; Graham Holder; Huub Jan Kleijn; Edwin Spaans; Joanna Udo De Haes; Marieke L de Kam; Kari L Franson; Adam F Cohen; Joop M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.